The U.S. Drug Enforcement Administration is asking a federal appeals court to throw out a lawsuit aimed at clearing a path to the therapeutic use of psilocybin, the main psychoactive compound in psychedelic mushrooms—arguing that allowing limited medical access could boost the illegal drug trade.